
A new once-a-day tablet that treats advanced breast cancer is to be rolled out on the NHS, with about 1,100 patients in England set to benefit.
The final guidance on elacestrant by the National Institute for Health and Care Excellence (Nice) comes after it provisionally rejected the drug in October.